Nirilla D. Anthonimuthu

Nirilla Anthonimuthu practices at NYC Health + Hospitals/South Brooklyn Health, Ruth Bader Ginsburg Hospital in Brooklyn, New York, part of NYC.

Nirilla Anthonimuthu's NPI, 1225040686, was assigned on August 13, 2006. Nirilla Anthonimuthu holds New York license 215178-1.

Nirilla Anthonimuthu's primary practice is NYC Health + Hospitals/South Brooklyn Health, Ruth Bader Ginsburg Hospital, at 2601 Ocean Parkway, Brooklyn, NY 11235 in Kings County. The practice phone is (718) 616-4834.

Nirilla Anthonimuthu's primary practice is NYC Health + Hospitals/South Brooklyn Health, Ruth Bader Ginsburg Hospital in Brooklyn, New York, part of NYC. Nirilla Anthonimuthu is also affiliated with NYC Health + Hospitals/Kings County. The medical group on file is Physician Affiliate Group of New York (PAGNY). Dmand AI also links Nirilla Anthonimuthu to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Nirilla Anthonimuthu practices, 2 sites in all. Vendor and product names are available with a free account.

Psychiatry is Nirilla Anthonimuthu's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Nirilla Anthonimuthu is licensed in New York.

CMS data shows 87 Medicare services from Nirilla Anthonimuthu across 3 procedure codes in 2024, for 37 Medicare patients. Medicare paid $6,417 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 37 Medicare patients who saw Nirilla Anthonimuthu in 2024. The largest group is under 65, with 26 patients. 75% of them have anxiety, and 75% have high cholesterol. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Nirilla Anthonimuthu's median patient age at 58, with 50% women.

In 2024, Nirilla Anthonimuthu wrote 150 Medicare Part D claims for 46 patients. 79% of them were for generic drugs. CMS names the drug for 30 of them, across 2 drugs with 11 or more claims each, at $442 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

Nirilla Anthonimuthu accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 3 general payments to Nirilla Anthonimuthu from 2 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $107.